Derazantinib and Atezolizumab in Patients With Urothelial Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 303
Summary
- Conditions
- Urothelial Carcinoma
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The study comprises five open-label substudies in patients with advanced urothelial cancer harboring FGFR GA who will be treated by derazantinib monotherapy or derazantinib in combination with atezolizumab. The study enrolls patients with cisplatin-ineligible status, or patients whose disease progre...
The study comprises five open-label substudies in patients with advanced urothelial cancer harboring FGFR GA who will be treated by derazantinib monotherapy or derazantinib in combination with atezolizumab. The study enrolls patients with cisplatin-ineligible status, or patients whose disease progressed after either first-line treatment or prior treatment with FGFR inhibitors.
Tracking Information
- NCT #
- NCT04045613
- Collaborators
- Not Provided
- Investigators
- Study Director: Manuel Häckl, MD Basilea Pharmaceutica International Ltd
Get Well Soon